Vnitr Lek 2025, 71(5):326-328

How to properly interpret lipid profile results

Vladimír Soška
Oddělení klinické biochemie, Fakultní nemocnice u sv. Anny v Brně
II. interní klinika, Lékařská fakulta MU, Brno

The lipid profile usually includes total cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol and calculation of non-HDL-cholesterol. It is optimal to evaluate the results in their mutual context, not in isolation as a single parameter. The concentration of triglycerides and total cholesterol is important for assessing whether atherogenic dyslipidemia is present, whether the LDL-cholesterol result can be relied on, and whether non-HDL-cholesterol can be used to estimate risk according to the SCORE2 tables. Lipoprotein(a) and apolipoprotein B can be used to specify the risk. It is also appropriate to take into account the reliability of blood lipid measurements, since the measurement of LDL-cholesterol, HDL-cholesterol and lipoprotein(a) is not standardized between laboratories.

Keywords: cholesterol, triacylglycerols, apolipoprotein B, lipoprotein(a).

Accepted: August 25, 2025; Published: September 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V. How to properly interpret lipid profile results. Vnitr Lek. 2025;71(5):326-328.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. Go to original source... Go to PubMed...
    2. SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Repatha 140MG INJ SOL 2x1ML, správní řízení sp. zn. SUKLS29290/2019, č. jedn. sukl4530/2021 ze dne 7. 1. 2021. SÚKL; 2021.
    3. SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Praluent 75 mg, F-CAU-003-02R/31. 08. 2018, Sp. zn. SUKLS85942/2019, č. jedn. sukl209748/2020, ze dne 20. 8. 2020. SÚKL; 2020.
    4. Martin SS, Giugliano RP, Murphy SA, et al. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018;3:749-753. Go to original source... Go to PubMed...
    5. Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5:540-548. Go to original source... Go to PubMed...
    6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502. Go to original source...
    7. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56:977-986. Go to original source... Go to PubMed...
    8. Contois JH, Warnick GR, Sniderman AD. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol. 2011;5:264-272. Go to original source... Go to PubMed...
    9. Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46-61. Go to original source... Go to PubMed...
    10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111-188. Go to original source... Go to PubMed...
    11. Langlois MR, Descamps OS, van der Laarse A, et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis. 2014;233:83-90. Go to original source... Go to PubMed...
    12. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007;28:2375-2414. Go to original source... Go to PubMed...
    13. Ko DT, Alter DA, Guo H, et al. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol. 2016;68:2073-2083. Go to original source... Go to PubMed...
    14. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478-2486. Go to original source... Go to PubMed...
    15. Doggrell SA. What have we learnt from the clinical outcomes trials with the cetrapibs? Curr Opin Lipidol. 2018;29:327-332. Go to original source... Go to PubMed...
    16. Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140:1308-1317. Go to original source... Go to PubMed...
    17. Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front Endocrinol (Lausanne). 2020;11:616. Go to original source... Go to PubMed...
    18. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-635. Go to original source... Go to PubMed...
    19. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925-3946. Go to original source... Go to PubMed...
    20. Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021;77:1576-1589. Go to original source... Go to PubMed...
    21. Ruhaak LR, Cobbaert CM. Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. Clin Chim Acta. 2020;511:260-268. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.